Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q1 2017 · 10-Q
Revenue$16.00K$16.00K−97.3% vs Q1 2016 Net Income-$7.52M-$7.52MN/M vs Q1 2016 EPS Diluted-$0.43-$0.43N/M vs Q1 2016 Operating Income-$7,987,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$6,597,000N/M Margins · derivedOperating margin-49918.8%−48977.3 pt vs Q1 2016
Net margin-46981.3%−46438.3 pt vs Q1 2016
ended Mar 31, 2017 · filed May 9, 2017 · 39 d after period end